- Home
- AMC vs SPRY Comparison
AMC vs SPRY Comparison
Compare AMC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMC
- SPRY
- Stock Information
- Founded
- AMC 1920
- SPRY 2015
- Country
- AMC United States
- SPRY United States
- Employees
- AMC N/A
- SPRY N/A
- Industry
- AMC Movies/Entertainment
- SPRY Biotechnology: Pharmaceutical Preparations
- Sector
- AMC Consumer Discretionary
- SPRY Health Care
- Exchange
- AMC Nasdaq
- SPRY Nasdaq
- Market Cap
- AMC 1.5B
- SPRY 1.4B
- IPO Year
- AMC 2013
- SPRY N/A
- Fundamental
- Price
- AMC $3.01
- SPRY $15.69
- Analyst Decision
- AMC Hold
- SPRY Strong Buy
- Analyst Count
- AMC 7
- SPRY 4
- Target Price
- AMC $3.92
- SPRY $28.75
- AVG Volume (30 Days)
- AMC 13.7M
- SPRY 1.2M
- Earning Date
- AMC 08-01-2025
- SPRY 08-05-2025
- Dividend Yield
- AMC N/A
- SPRY N/A
- EPS Growth
- AMC N/A
- SPRY N/A
- EPS
- AMC N/A
- SPRY N/A
- Revenue
- AMC $4,548,300,000.00
- SPRY $97,122,000.00
- Revenue This Year
- AMC $8.36
- SPRY N/A
- Revenue Next Year
- AMC $6.63
- SPRY $140.40
- P/E Ratio
- AMC N/A
- SPRY N/A
- Revenue Growth
- AMC N/A
- SPRY 971120.00
- 52 Week Low
- AMC $2.45
- SPRY $7.55
- 52 Week High
- AMC $5.76
- SPRY $18.51
- Technical
- Relative Strength Index (RSI)
- AMC 43.56
- SPRY 60.81
- Support Level
- AMC $3.08
- SPRY $14.77
- Resistance Level
- AMC $3.54
- SPRY $16.23
- Average True Range (ATR)
- AMC 0.13
- SPRY 0.73
- MACD
- AMC -0.06
- SPRY 0.12
- Stochastic Oscillator
- AMC 5.17
- SPRY 84.68
About AMC AMC Entertainment Holdings Inc.
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. It owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.